ALK rearrangement in non-small cell lung cancer

被引：0
作者：
Naulleau, Gaspard [1 ]
Birsen, Gary [1 ]
Mansuet-Lupo, Audrey [2 ,3 ]
Leroy, Karen [4 ]
Wislez, Marie [1 ,3 ]
机构：
[1] Univ Paris Cite, Hop Cochin, AP HP Ctr, Serv Pneumol, Paris, France
[2] Univ Paris Cite, Hop Cochin, AP HP Ctr, Serv Anat Pathol, Paris, France
[3] Univ Paris Cite, Ctr Rech Cordeliers, Equipe Inflammat Complement & Canc, INSERM,U1138, Paris, France
[4] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Serv Biochim, Paris, France
来源：
BULLETIN DU CANCER | 2025年 / 112卷 / 03期
关键词：
ALK rearrangement; Targeted therapy; Non-small cell lung carcinoma; Resistance mechanisms; GENERATION SEQUENCING REVEALS; RECEPTOR TYROSINE KINASE; EML4-ALK FUSION GENE; HISTOLOGICAL TRANSFORMATION; NSCLC PATIENTS; RESISTANCE; ADENOCARCINOMA; CRIZOTINIB; MUTATION; ALECTINIB;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The discovery of ALK gene rearrangement in 3 to 5% of non-small cell lung carcinomas has revolutionized our understanding and therapeutic approach of these cancers. This oncogenic driver is associated with specific clinical and biological features is associated with specific clinical and biological features, mainly affecting young and never-smoker patients, with a particular tropism outcomes, with remarkable efficacy of latest-generation molecules, particularly in controlling brain metastases. However, the emergence of complex resistance mechanisms, whether ALK-dependent or ALK-independent, remains a major challenge. The comprehensive understanding of these resistance mechanisms now guides the development of next-generation inhibitors and innovative therapeutic strategies, paving the way for increasingly personalized precision medicine.
引用
收藏
页码：3S86 / 3S94
页数：9
相关论文
共 68 条
  • [1] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient
    Ai, Xinghao
    Niu, Xiaomin
    Chang, Lianpeng
    Chen, Rongrong
    Ou, Sai-Hong Ignatius
    Lu, Shun
    [J]. LUNG CANCER, 2018, 123 : 83 - 86
  • [2] Ambrosini P, 2025, CLIN LUNG CANCER, V26, pe11, DOI [10.1016/j.clc.2024.11.012, 10.1016/j.cllc.2024.11.012]
  • [3] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) : 2027 - 2039
  • [4] A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
    Cha, Yoon Jin
    Cho, Byoung Chul
    Kim, Hye Ryun
    Lee, Hye-Jeong
    Shim, Hyo Sup
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) : E55 - E58
  • [5] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
    Choi, Young Lim
    Soda, Manabu
    Yamashita, Yoshihiro
    Ueno, Toshihide
    Takashima, Junpei
    Nakajima, Takahiro
    Yatabe, Yasushi
    Takeuchi, Kengo
    Hamada, Toru
    Haruta, Hidenori
    Ishikawa, Yuichi
    Kimura, Hideki
    Mitsudomi, Tetsuya
    Tanio, Yoshiro
    Mano, Hiroyuki
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1734 - 1739
  • [6] Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib
    Coleman, Niamh
    Wotherspoon, Andrew
    Yousaf, Nadia
    Popat, Sanjay
    [J]. LUNG CANCER, 2019, 134 : 117 - 120
  • [7] Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
    Desai, Aakash
    Lovly, Christine M.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 615 - 628
  • [8] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Pilling, Amanda B.
    Aisner, Dara L.
    Kutateladze, Tatiana G.
    Le, Anh T.
    Weickhardt, Andrew J.
    Kondo, Kimi L.
    Linderman, Derek J.
    Heasley, Lynn E.
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1472 - 1482
  • [9] NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
    Drilon, Alexander
    Horan, Joshua C.
    Tangpeerachaikul, Anupong
    Besse, Benjamin
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Camidge, D. Ross
    Wekken, Anthonie J. van der
    Nguyen-Phuong, Linh
    Acker, Adam
    Keddy, Clare
    Nicholson, Katelyn S.
    Yoda, Satoshi
    Mente, Scot
    Sun, Yuting
    Soglia, John R.
    Kohl, Nancy E.
    Porter, James R.
    Shair, Matthew D.
    Zhu, Viola
    Davare, Monika A.
    Hata, Aaron N.
    Pelish, Henry E.
    Lin, Jessica J.
    [J]. CANCER DISCOVERY, 2023, 13 (03) : 598 - 615
  • [10] Prospective screening for ALK: Clinical features and outcome according to ALK status
    Fallet, Vincent
    Cadranel, Jacques
    Doubre, Helene
    Toper, Cecile
    Monnet, Isabelle
    Chinet, Thierry
    Oliviero, Gerard
    Foulon, Guillaume
    De Cremoux, Hubert
    Vieira, Thibault
    Antoine, Martine
    Wislez, Marie
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) : 1239 - 1246
1234567